MedTrace Logo

Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure

NCT04442048 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 195

Last updated 2025-12-30

No results posted yet for this study

Summary

The purpose of this study is to find out if immunization with IMM-101 will reduce the incidence of severe respiratory and COVID-19 infections in cancer patients.

Conditions

Interventions

BIOLOGICAL

IMM-101

Three doses of IMM-101 on days 0, 14, and 45.

OTHER

Observation

No active treatment. Observation only

Sponsors & Collaborators

  • Immodulon Therapeutics Ltd

    collaborator INDUSTRY

  • BioCan Rx

    collaborator UNKNOWN

  • Canadian Cancer Society (CCS)

    collaborator OTHER

  • ATGen Canada Inc

    collaborator INDUSTRY

  • Canadian Centre for Applied Research in Cancer Control (ARCC)

    collaborator UNKNOWN

  • Ontario Institute for Cancer Research

    collaborator OTHER

  • Canadian Cancer Trials Group

    lead NETWORK

Principal Investigators

  • Rebecca A Auer · Ottawa Hospital Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2024-05-07
Completion
2025-12-22

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04442048 on ClinicalTrials.gov